We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Scientists Create, Watch Tumor-Fighting Immune Cells Attack Cancer

By LabMedica International staff writers
Posted on 10 Aug 2010
Researchers have created a large, well-stocked army of tumor-seeking immune system cells, which they could see in real time, using positron emission tomography (PET) imaging as the cellular payload traveled throughout the body to locate and attack deadly melanomas.

The gene therapy research, conducted with melanomas grown in mice, utilized an inactive HIV-like virus to serve as a vehicle to arm the lymphocytes with T cell receptors, which caused the lymphocytes to become specific killers of cancerous cells. More...
A reporter gene, which glows "hot” during PET scanning, also was inserted into the cells so researchers could track the genetically engineered lymphocytes after they were injected into the blood stream, made their way to the lungs and lymph nodes, and then specifically homed in on the tumors wherever they were located within the body.

"We're trying to genetically engineer the immune system to become a cancer killer and then image how the immune system operates at the same time,” said Dr. Antoni Ribas, an associate professor of hematology/oncology, a researcher at the University of California, Los Angeles' (UCLA) Jonsson Comprehensive Cancer Center (USA) and the senior author of the study. "We knew this approach of arming the lymphocytes with T cell receptors showed significant antitumor activity based on studies in humans. Now, by tracking the immune system's reaction to cancer and imaging it in real time, we can project how the same process that succeeded in mice might behave in people.”

The study was published July 12, 2010, in the early online issue of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS). "The novelty of our work is that we were able to pack together the cancer specific T cell receptor and the PET reporter genes in a single vector and use it in mice with an intact immune system that closely resembles what we would see in real patients,” stated Dr. Richard Koya, an assistant professor of surgical oncology at UCLA's David Geffen School of Medicine, and first author of the study. "We were also gladly surprised to see the targeted tumors literally melt away and disappear, underscoring the power of the combined approach of immune and gene therapy to control cancer.”

The immune system typically does not recognize cancer cells in the body as enemies. The insertion of the antigen-specific T cell receptors--modified to seek out a tumor antigen on the surface of the melanoma cells--in effect uncovers the malignant cells, revealing them as lethal invaders that must be sought out and destroyed. By imaging the genetically modified T cells as they seek out and attack the cancer, the scientists can closely examine the processes of the immune system as it fights malignancies, which could then result in better monitoring response to therapy in melanoma patients.

In this study, the cells were injected into the bloodstreams of the mice, which were found to begin to fight the melanoma within two to three days. The mice were imaged periodically for 10 days to ensure the lymphocytes were indeed killing the cancer. The process to find and kill the malignant cells could take longer in people, according to Dr. Ribas.

If a patient's tumor did not respond well to the administration of the genetically engineered T cells, scientists could determine by PET scanning whether the cells had not successfully made it to the tumor site or, if they did arrive, whether or not they functioned as expected. Monitoring the immune response also could provide insights into ways to better engineer the lymphocytes to more effectively enter and attack the tumors.

In this study, about one million genetically engineered lymphocytes were created and injected into a mouse. In humans, the number of tumor-seeking cells needed to fight the cancer is approximately one billion, according to Dr. Ribas. He and his team are working now on creating a vector, or vehicle, to insert the T cell receptors and reporter gene into the lymphocytes in a way that is safe to use in humans. If all goes well, human studies of the process could begin in approximately one year, Dr. Ribas noted.

Related Links:
University of California, Los Angeles' Jonsson Comprehensive Cancer Center



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.